These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36585770)

  • 21. Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen.
    Santoro MM; Fornabaio C; Malena M; Galli L; Poli A; Menozzi M; Zazzi M; White KL; Castagna A;
    Int J Antimicrob Agents; 2020 Jul; 56(1):106027. PubMed ID: 32450199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro analysis of the replicative capacity and phenotypic susceptibility to integrase inhibitors of HIV-2 mutants with integrase insertions.
    Le Hingrat Q; Collin G; Damond F; Peytavin G; Lebourgeois S; Ghosn J; Bachelard A; Ferré VM; Matheron S; Descamps D; Charpentier C
    J Antimicrob Chemother; 2022 Feb; 77(2):409-412. PubMed ID: 34741606
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.
    Hassounah SA; Alikhani A; Oliveira M; Bharaj S; Ibanescu RI; Osman N; Xu HT; Brenner BG; Mesplède T; Wainberg MA
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary resistance against integrase strand transfer inhibitors in integrase strand transfer inhibitor-naive patients failing first- and second-line ART in Tanzania.
    Henerico S; Lyimo E; Makubi AN; Magesa D; Desderius B; Mueller A; Changalucha J; Kalluvya SE; Van Zyl G; Preiser W; Mshana SE; Kasang C
    J Antimicrob Chemother; 2022 Oct; 77(11):3138-3143. PubMed ID: 36101479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance.
    Hachiya A; Ode H; Matsuda M; Kito Y; Shigemi U; Matsuoka K; Imamura J; Yokomaku Y; Iwatani Y; Sugiura W
    Antiviral Res; 2015 Jul; 119():84-8. PubMed ID: 25956162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrase Strand Transfer Inhibitor Resistance in Integrase Strand Transfer Inhibitor-Naive Persons.
    Bailey AJ; Rhee SY; Shafer RW
    AIDS Res Hum Retroviruses; 2021 Oct; 37(10):736-743. PubMed ID: 33683148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of integrase strand transfer inhibitor resistance mutations in antiretroviral-naive HIV-1-infected individuals in Cameroon.
    Wenk BM; Mbunkah HA; Nsanwe NN; Mbu ET; Besong LM; Sama BA; Orock E; Leemann C; Metzner KJ
    J Antimicrob Chemother; 2021 Jan; 76(1):124-129. PubMed ID: 32954411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural effects of HIV-1 subtype C integrase mutations on the activity of integrase strand transfer inhibitors in South African patients.
    Mbhele N; Gordon M
    J Biomol Struct Dyn; 2022; 40(23):12546-12556. PubMed ID: 34488561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings.
    Semengue ENJ; Armenia D; Inzaule S; Santoro MM; Dambaya B; Takou D; Teto G; Nka AD; Yagai B; Fabeni L; Chenwi C; Angong Beloumou G; Djupsa Ndjeyep SC; Colizzi V; Perno CF; Ceccherini-Silberstein F; Fokam J
    J Antimicrob Chemother; 2021 Apr; 76(5):1277-1285. PubMed ID: 33501504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: a cross-sectional analysis of a Northeast Nigerian cohort.
    Abdullahi A; Kida IM; Maina UA; Ibrahim AH; Mshelia J; Wisso H; Adamu A; Onyemata JE; Edun M; Yusuph H; Aliyu SH; Charurat M; Abimiku A; Abeler-Dorner L; Fraser C; Bonsall D; ; Kemp SA; Gupta RK
    J Antimicrob Chemother; 2023 Aug; 78(8):2000-2007. PubMed ID: 37367727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiviral activity of HIV-1 integrase strand-transfer inhibitors against mutants with integrase resistance-associated mutations and their frequency in treatment-naïve individuals.
    Margot NA; Ram RR; White KL; Abram ME; Callebaut C
    J Med Virol; 2019 Dec; 91(12):2188-2194. PubMed ID: 31389026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naive individuals: results from a European multi-cohort study.
    Rossetti B; Fabbiani M; Di Carlo D; Incardona F; Abecasis A; Gomes P; Geretti AM; Seguin-Devaux C; Garcia F; Kaiser R; Modica S; Shallvari A; Sönnerborg A; Zazzi M;
    J Antimicrob Chemother; 2021 Aug; 76(9):2394-2399. PubMed ID: 34212176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-1 diversity and pre-treatment drug resistance in the era of integrase inhibitor among newly diagnosed ART-naïve adult patients in Luanda, Angola.
    Sebastião CS; Abecasis AB; Jandondo D; Sebastião JMK; Vigário J; Comandante F; Pingarilho M; Pocongo B; Cassinela E; Gonçalves F; Gomes P; Giovanetti M; Francisco NM; Sacomboio E; Brito M; Neto de Vasconcelos J; Morais J; Pimentel V
    Sci Rep; 2024 Jul; 14(1):15893. PubMed ID: 38987263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-1 Integrase Inhibitors That Are Active against Drug-Resistant Integrase Mutants.
    Smith SJ; Zhao XZ; Passos DO; Lyumkis D; Burke TR; Hughes SH
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32601157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unravelling the dynamics of selection of multiresistant variants to integrase inhibitors in an HIV-1-infected child using ultra-deep sequencing.
    Stefic K; Salmona M; Capitao M; Splittgerber M; Maakaroun-Vermesse Z; Néré ML; Bernard L; Chaix ML; Barin F; Delaugerre C
    J Antimicrob Chemother; 2017 Mar; 72(3):850-854. PubMed ID: 27999055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance.
    Mbhele N; Chimukangara B; Gordon M
    Int J Antimicrob Agents; 2021 May; 57(5):106343. PubMed ID: 33852932
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparable
    Saladini F; Giannini A; Boccuto A; Dragoni F; Appendino A; Albanesi E; Vicenti I; Zazzi M
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31611362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting.
    d'Arminio Monforte A; Cozzi-Lepri A; Di Biagio A; Marchetti G; Lo Caputo S; Rusconi S; Gianotti N; Mazzotta V; Mazzarello G; Costantini A; Castagna A; Antinori A;
    J Antimicrob Chemother; 2019 May; 74(5):1363-1367. PubMed ID: 30698801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings.
    Armenia D; Santoro MM; Charpentier C; Bertoli A; Forbici F; Calvez V; Descamps D; Ceccherini-Silberstein F; Marcelin AG; Flandre P
    J Antimicrob Chemother; 2023 Jun; 78(6):1415-1422. PubMed ID: 37258034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding.
    Chitongo R; Obasa AE; Mikasi SG; Jacobs GB; Cloete R
    PLoS One; 2020; 15(5):e0223464. PubMed ID: 32379830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.